Shire in preliminary talks with Barr on Adderall settlement

Shire Pharmaceuticals has confirmed that it is in preliminary talks with a rival generic drug company to settle litigation over its hyperactivity drug Adderall. News of the talks instantly sent Shire shares higher. Shire has been involved in litigation with Barr Pharmaceuticals, which is looking to release a generic version of Adderall. Shire has said it will defend its patent on Adderall until it expires in 2018, but now says it won't rule out a deal that opens the way to a cheaper medication prior to that.

- read this story from the BBC for more

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.